Clinical Trial Update: A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial update announcing a study of HLX22 in combination with HLX87 for HER2-positive recurrent or metastatic breast cancer, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HLX22
• HLX87 (HLX87)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: HER2 + Breast Cancer | Phase 2, Phase 3 | Status: RECRUITING